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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
type of childhood cancer.1 Annually, approximately 120 new
cases of childhood ALL are diagnosed in the Netherlands. The
treatment of childhood ALL has improved dramatically and
survival increased from 0-5% in the 1960s to 80-85% nowa-
days.1 Treatment consists of induction, consolidation, intensi-
fication and continuation phases. Asparaginase is one of the
key drugs in this treatment.2-4 Asparaginase is a non-human
enzyme which hydrolyses asparagine into aspartic acid and
ammonia. Given that leukemic blasts depend heavily on
asparagine, deprived of this amino acid, they undergo apop-
tosis.5
Currently, several asparaginase preparations are available
on the market: these are derived from Escherichia coli in its
native form (Paronal® or Asparaginase medac®) or as a pegy-
lated enzyme (PEGasparaginase, Oncaspar®) or extracted
from Erwinia chrysanthemi (Erwinia asparaginase, Erwinase®).
Many studies have shown that intensification by asparagi-
nase is essential to improve the event-free survival of chil-
dren with ALL.2-4,6-8
Unfortunately, asparaginase can cause an allergic reaction
leading to inactivation of the drug or silent inactivation. Silent
inactivation is the formation of anti-asparaginase antibodies
which neutralize asparaginase without their being clinical
symptoms of an allergy.9 In the case of allergic reactions to
PEGasparaginase, Erwinia asparaginase is given instead. Erwinia
asparaginase is given three times per week. The different dose
schedules for native E. coli asparaginase, PEGasparaginase and
Erwinia asparaginase are based on differences in the pharmaco-
kinetics of the three products.
Compared to native E. coli asparaginase, PEGasparaginase is
expensive,10 and Erwinia asparaginase is even more expensive.
Little information is available on the exact costs of asparaginase
in the treatment of ALL.11-12 Recently, Litsenburg et al.13 conclud-
ed that medication and diagnostics were the major contributors
to the increased costs of the ALL-10 protocol compared to the
previous ALL-9 protocol. However, in this study the costs of
asparaginase were not analyzed separately and the costs were
not related to the occurrence of allergies. Since native E. coli
asparaginase was not administered during intensification in the
ALL-10 protocol, we used hypothetical scenarios to study this
strategy. The trial data of the ALL-10 protocol were used to
compare PEGasparaginase to native E. coli asparaginase.
Because of hospital budget restrictions and increasing costs of
treatment of childhood ALL more insight into costs of asparag-
inase preparations is desired.
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Asparaginase is an expensive drug, but important in childhood acute lymphoblastic leukemia. In order to compare
costs of PEGasparaginase, Erwinia asparaginase and native E. coli asparaginase, we performed a cost-analysis in the
Dutch Childhood Oncology Group ALL-10 medium-risk group intensification protocol. Treatment costs were cal-
culated based on patient level data of 84 subjects, and were related to the occurrence of allergy to PEGasparaginase.
Simultaneously, decision tree and sensitivity analyses were conducted. The total costs of the intensification course
of 30 weeks were $57,893 in patients without PEGasparaginase allergy (n=64). The costs were significantly higher
($113,558) in case of allergy (n=20) necessitating a switch to Erwinia asparaginase. Simulated scenarios (decision
tree analysis) using native E. coli asparaginase in intensification showed that the costs of PEGasparaginase were
equal to those of native E. coli asparaginase. Also after sensitivity analyses, the costs for PEGasparaginase were
equal to those of native E. coli asparaginase. Intensification treatment with native E. coli asparaginase, followed by
a switch to PEGasparaginase, and subsequently to Erwinia asparaginase in case of allergy had similar overall costs
compared to the treatment with PEGasparaginase as the first-line drug (followed by Erwinia asparaginase in the
case of allergy). PEGasparaginase is preferred over native E. coli asparaginase, because it is administered less fre-
quently, with less day care visits. PEGasparaginase is less immunogenic than native E. coli asparaginase and is not
more expensive. Asparaginase costs are mainly determined by the percentage of patients who are allergic and
require a switch to Erwinia asparaginase.
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ABSTRACT
In the present study, we studied the costs of asparaginase
in childhood ALL patients treated with PEGasparaginase or
Erwinia asparaginase during the first 30 weeks of the inten-
sification phase of the ALL-10 medium-risk (MR) protocol.
The aim was to assess whether there are savings from using
PEGasparaginase as the first-line drug rather than the native
E.coli asparaginase.
Design and Methods 
Overall study design
For this cost-analysis, we compared the costs of asparag-
inase related to allergy in three treatment scenarios.
Scenario 1 is based on trial data from the ALL-10 MR pro-
tocol. Scenarios 2 and 3 are based on assumptions. A deci-
sion tree model was also used to relate costs for each sce-
nario to different allergy rates. 
Patients and the acute lymphoblastic leukemia 
treatment protocol
From November 2004 to April 2012, children with ALL
were enrolled on the DCOG ALL-10 protocol14 approved by
the Institutional Review Board. Patients were stratified into
three risk groups after induction treatment: standard risk
(SR), MR and high risk (HR).15 The intensification/continua-
tion scheme for the ALL-10 MR patients, including asparag-
inase (administered intravenously) is shown in Online
Supplementary Figure S1 and described in the Online
Supplementary Design and Methods section. For this cost-
analysis between April 2005 and October 2009, only MR
patients from two pediatric oncology centers were includ-
ed. Allergic reactions were graded according to the National
Cancer Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. 
Description of three scenarios
The ALL-10 MR protocol was used as scenario 1 (Figure
1). Due to the fact that native E. coli asparaginase was not
administered during intensification in this protocol, we
used two hypothetical scenarios. In scenarios 2 and 3,
patients were hypothetically treated with native E. coli
asparaginase (5,000 IU/m2, twice weekly) for a duration of
30 weeks (Figure 1). In scenario 2, in case of an allergic reac-
tion to native E. coli asparaginase, Erwinia asparaginase was
given. In scenario 3, patients were switched to
PEGasparaginase in case of an allergic reaction to native E.
coli asparaginase. Scenario 3 was based, among others, on
the ALL-10 induction and the ALL-BFM 200016 protocols
which prescribed PEGasparaginase as second-line and
Erwinia asparaginase as third-line therapy. In this scenario, it
was assumed that an allergy to PEGasparaginase after an
allergic reaction to native E. coli asparaginase will occur at
the second dose which is the case in practically all allergic
reactions according to the interim results of the ALL-10 pro-
tocol. 
Costs data
Data on volumes were adapted from hospital electronic
databases and medical files. For the unit prices, we applied
the microcosting method17 and Dutch tariffs. More details
are given in the Online Supplementary Design and Methods
section.
Statistical, decision tree, sensitivity analyses
The data were analyzed with the software package SPSS
for Windows version 17.0.2 (SPSS, Chicago, IL, USA). The
mean total costs were not normally distributed (as shown
by the Shapiro-Wilk test). The non-parametric Mann-
Whitney U-test was used to compare the subgroups with or
without an allergy to asparaginase. A two-sided P-value
<0.05 was considered statistically significant. Data are pre-
sented as mean ± standard deviation and median (range)
where appropriate.
We developed a decision tree model to compare costs of
PEGasparaginase or Erwinia asparaginase to those of native
E.coli asparaginase, while taking into account the incidence
of allergy to asparaginase and the different associated costs
W.H. Tong et al.
754 haematologica | 2013; 98(5)
Figure 1. The flow-
chart of three dis-
tinct scenarios of
asparaginase treat-
ment in children with
acute lymphoblastic
leukemia.
First-line Second-line Third-line
PEGasparaginase
(iv.; 2,500 IU/m2; 1x
per 2 weeks)
Erwinia asparaginase
(iv.; 20,000 IU/m2; 3x
per week)
Erwinia asparaginase
(iv.; 20,000 IU/m2; 3x
per week)
Erwinia asparaginase
(iv.; 20,000 IU/m2; 3x
per week)
PEGasparaginase
(iv.; 2,500 IU/m2; 1x
per 2 weeks)
Native E. coli
asparaginase
(iv.; 5,000 IU/m2;
1x per 3 days)
Native E. coli
asparaginase
(iv.; 5,000 IU/m2;
1x per 3 days)
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(Figure 2). To account for uncertainty in the used prices and
calculated costs, sensitivity analyses were performed. More
details are given in the Online Supplementary Design and
Methods section.
Results
Characteristics
In total 84 children with ALL (33 girls) were included in
this study. The median age was 5.2 years (range, 1.8-18.6
years) at the start of the intensification. The baseline char-
acteristics of each subgroup are presented in Table 1. In total
20 patients (24%) were switched to Erwinia asparaginase
because of a proven allergic reaction to PEGasparaginase
(grade 2 or higher according to the CTCAE criteria). No
grade 1 allergies were seen. Two patients had an allergy to
PEGasparaginase in a period (June 2005) that no Erwinia
asparaginase was commercially available in the
Netherlands. Five patients were switched to twice weekly
Erwinia asparaginase based on sufficient trough asparagi-
nase levels.
Calculated costs (scenario 1)
Table 2 presents the costs per subgroup for all patients.
The total mean treatment costs of all patients treated
according to the first 30 weeks of the ALL-10 MR protocol
were $ 71,147±35,763 per patient. The distribution of these
costs was mainly accounted for by asparaginase use (47%)
calculated per used vial. Day care treatment and inpatient
care accounted for 15% of the total costs. The mean treat-
ment costs for patients with no allergy to PEGasparaginase
were $ 57,893±16,247 per patient, which was significantly
lower than the costs of the subgroup with an allergy to
PEGasparaginase ($ 113,558±47,187 per patient). The total
costs were calculated per 2 weeks of asparaginase exposure;
for PEGasparaginase ($ 3,860±1,083 per patient), and for
Erwinia asparaginase ($ 7,571±3,146 per patient).
Simulated costs (scenario 2 and 3)
Table 3 shows the mean costs of the two hypothetical
scenarios with native E. coli asparaginase administered. The
mean costs would be $ 47,610±13,317 for the subgroup
with no allergy to native E. coli asparaginase. These costs
were significantly lower than for patients who developed
an allergy to native E. coli asparaginase and switched to
Erwinia asparaginase with mean costs of $ 133,554±31,252
(P<0.001, scenario 2). A switch from native E. coli asparagi-
nase to PEGasparaginase was accompanied by mean costs
of $ 53,978±24,538, which are higher but not statistically
significantly so, than the costs in the group without an aller-
gy to native E. coli asparaginase. A second switch in the
intensification to Erwinia asparaginase after an allergy to
PEGasparaginase had a cost of $ 125,719±30,623 (P<0.001,
scenario 3). 
Decision tree and sensitivity analyses
The decision tree analysis was used to relate costs for
each scenario to different probabilities of allergy. Figure 2
shows that the treatment costs using either native E. coli
asparaginase as the first-line preparation (scenario 3: $
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Figure 2. Decision tree of asparaginase treatment in children with acute lymphoblastic leukemia in intensification according to three sce-
narios. The mean costs after each probability of allergy (P) are the calculated costs per patient in scenario 1. The costs at the end of each
branch represent the multiplied costs with each probability of allergy. The costs in scenarios 2 and 3 are simulated costs. The costs after
each probability of allergy are the costs per patient. The costs at the end of each branch represent the multiplied costs with each probability
of allergy in scenarios 2 and 3. In the last branch of scenario 3, the costs are calculated by multiplying the probability of allergy of 0.65
with the allergy probabilities of 0.6 and 0.4, respectively.
Table 1. Characteristics of patients with and without an allergic reac-
tion to PEGasparaginase.
Characteristic No PEG-asp allergy PEG-asp allergy
Patients (%) 64 (76) 20 (24)
Boys / girls 37 / 27 14 / 6
Age (years), median (range) 5.4 (1.8-18.6) 4.3 (2-14.4)
Body surface area (m2),  0.8 (0.5-2) 0.8 (0.5-1.6)
median (range)
Patients age < 6 years (%) 35 (42) 12 (14)
Patients aged 6-12 years (%) 18 (22) 6 (7)
Patients aged > 12 years (%) 11 (13) 2 (2)
Daycare visits, median (range) 28 (19-42) 61 (6-84)
Inpatient days, median (range) 7 (0-40) 3 (0-77)
PEG-asp infusions, median (range) 15 (14-16) 2 (2)
Time point of PEG-asp allergy na 2 (2-4)
in weeks, median (range)
Erw-asp infusions, median (range) na 68 (10-84)
ALL-10 MRG: ALL-10 protocol medium risk group; PEG-asp: PEGasparaginase; Erw-asp:
Erwinia asparaginase; na: not applicable.
PEGasparaginase (scenario 1)
No asparaginase allergy
P=0.75 $57,893
P=0.25 $113,558
P=0.35 $47,610
P=0.65 $133,554
P=0.35 $47,610
P=0.4 $125,719
P=0.6 $53,978
$16,664
$16,664
$71,810
$28,390 +
$86,810 +
$103,474
$21,051
$32,687 +
$70,402
P=0.65
$43,420
No asparaginase allergy
No PEGasparaginase allergy
No asparaginase allergy
PEGasparaginase allergy -> Erwinia asparaginase
PEGasparaginase allergy -> Erwinia asparaginase
native E. coli asparaginase allergy -> Erwinia asparaginase
native E. coli asparaginase allergy -> PEGasparaginase
native E.coli asparaginase (scenario 2)
native E.coli asparaginase (scenario 3)
ALL 10 MR
70,402) or PEGasparaginase as the first-line preparation
(scenario 1: $ 71,810) were the lowest. The costs of using
native E. coli asparaginase in the first-line followed by
Erwinia asparaginase second line (scenario 2) would be
higher ($ 103,474).
One-way sensitivity analysis (Figure 3) showed that the
largest range in treatment costs was in the subgroup with
allergy to native E. coli asparaginase (scenario 2).
Furthermore, Figure 3 illustrates that when treatment costs
were calculated with the new price of Erwinia asparaginase,
treatment with PEGasparaginase as the first-line prepara-
tion (scenario 1) would be less expensive ($ 100,199) than
treatment with the native E. coli asparaginase scenario 2 ($
190,284) and scenario 3 ($ 103,089).
Two-way sensitivity analysis (Figure 4) revealed that
treatment with PEGasparaginase (scenario 1) is less expen-
sive than treatment with native E. coli asparaginase (sce-
nario 2) for probabilities of allergy to PEGasparaginase rang-
ing from zero to 0.8 with a fixed allergy rate to native E. coli
asparaginase of 0.65 (Figure 4A). This also holds true if a
fixed allergy rate to native E. coli asparaginase of 0.4 is used,
which is frequently found in studies using less native E. coli
asparaginase in intensification after native E. coli asparagi-
nase in induction.16,18 The treatment with PEGasparaginase
(scenario 1) carries equal costs compared to the treatment
with native E. coli asparaginase (scenario 3) at a fixed rate of
allergy to PEGasparaginase of 0.25 (Figure 4B,C). This holds
true if the probabilities for a second allergy to
PEGasparaginase allergy are lower than the base case value
of 0.4 (Figure 4B) or if the allergy probabilities for native E.
coli asparaginase are higher than the base case value of 0.65
(Figure 4C).
Discussion
The aim of this study was to assess whether there could
be savings from using PEGasparaginase as the first-line drug
compared to native E.coli asparaginase during the first 30
weeks of the intensification phase of the ALL-10 MR proto-
col in the Netherlands. We showed that overall costs of
treatment with native E. coli asparaginase, followed by a
switch to PEGasparaginase, and subsequently to Erwinia
asparaginase in case of allergy were $ 70,402. This sum was
equivalent to that of treatment with PEGasparaginase as the
first-line drug (followed by Erwinia asparaginase in case of
allergy) which had overall costs of $ 71,810 (scenario 1), as
applied in the ALL-10 MR protocol. Because of the compa-
rable costs of these two scenarios, the latter one is prefer-
able, because PEGasparaginase is administered less fre-
quently (once every 2 weeks versus four times every 2
weeks), resulting in a reduced burden for the patient and
family. Treatment with native E. coli asparaginase, followed
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Table 2. Treatment costs with PEGasparaginase (scenario 1) for patients with
and without an allergic reaction to PEGasparaginase. Scenario 1:
PEGasparaginase used as first-line treatment in intensification; and switch to
Erwinia asparaginase as second-line after PEGasparaginase allergy.
                                           No PEG-asp allergy           PEG-asp allergy             P
                                           median (mean; SD)         median (mean; SD)
                                                        ($)                                  ($)                        
Cost category
Chemotherapy without ASP   1,026 (1,163; 450)                 949 (1,143; 422)               0.6
PEG-asp per used vials        24,465 (27,324; 7,785)          3,262 (5,384; 4,642)        <0.001
Erw-asp per used vials                          na                        81,900 (66,424; 34,580)          -
Additional medication            1,467 (2,589; 3,750)            2,110 (4,027; 5,341)           0.03
Daycare treatment                 8,627 (8,931; 2,2062)         21,667 (20,202; 8,854)      <0.001
Inpatient care                          5,181 (8,879; 9,741)           2,827 (9,138; 16,792)           0.4
Blood products                           143 (609; 1,412)                       0 (43; 105)                  0.05
Laboratory activities               2,498 (3,089; 1,573)            2,055 (2,505; 1,911)           0.04
Other hospital activities        4,812 (5,310; 2,184)            3,981 (4,692; 2,718)            0.2
Total costs                             54,587 (57,893; 16,247)    126,613 (113,558; 47,187)   <0.001
PEG: poly-ethylene glycol; ASP:  asparaginase; PEG-asp:  PEGasparaginase; Erw-asp:  Erwinia
asparaginase; na: not applicable.
Table 3. Treatment costs according to two different hypothetical treatments (scenarios 2 and 3). Scenario 2: hypothetical treatment scenario with native
E. coli asparaginase used as first-line treatment; and switch to Erwinia asparaginase as second-line treatment after allergy to native E.coli asparaginase.
Scenario 3: hypothetical treatment scenario with native E. coli asparaginase used as first-line treatment; PEGasparaginase used as second-line after
native E.coli asparaginase allergy; and switch to Erwinia asparaginase as third-line treatment after PEGasparaginase allergy.
Native E.coli asp as first line, Erwinia asp Native E.coli asp as first line, PEG-asp as second line 
as second line and Erwinia asp as third line
No PEG-asp allergy PEG-asp allergy No PEG-asp allergy Only E.coli asp allergy E.coli ASP allergy and 
PEG-asp allergy
Cost category median (mean; SD) ($) median (mean; SD) ($) median (mean; SD) ($) median (mean; SD) ($) median (mean; SD) ($)
Chemotherapy without asp 1,026 (1,163; 450) 949 (1,143; 422) 1,026 (1,163; 450) 949 (1,143; 422) 949 (1,143; 422)
E.coli asp per used vials 5,337 (5,503; 936) 178 (222; 140) 5,337 (5,503; 936) 178 (222; 140) 178 (222; 140)
PEG-asp per used vials na na na 22,834 (23,731; 5,278) 3,262 (3,425; 729)
Erw-asp per used vials na 76,650 (87,439; 21,900) na na 68,250 (77,936; 19,412)
Additional medication 1,846 (2,981; 3,757) 2,148 (4,129; 5,388) 1,846 (2,981; 3,757) 2,046 (3,985; 5,345) 2,100 (4,042; 5,350)
Outpatient care 19,843 (20,076; 449) 24,341 (24,244; 213) 19,843 (20,076; 449) 8,438 (8,519; 363) 22,718 (22,572; 307)
Inpatient care 5,181 (8,879; 9,741) 2,827 (9,138; 16,792) 5,181 (8,879; 9,741) 2,827 (9,138; 16,792) 2,827 (9,138; 16,792)
Blood products 143 (609; 1,412) 0 (43; 105) 143 (609; 1,412) 0 (43; 105) 0 (43; 105)
Laboratory activities 2,498 (3,089; 1,573) 2,055 (2,505; 1,911) 2,498 (3,089; 1,573) 2,055 (2,505; 1,911) 2,055 (2,505; 1,911)
Other hospital activities 4,812 (5,310; 2,184) 3,981 (4,692; 2,718) 4,812 (5,310; 2,184) 3,981 (4,692; 2,718) 3,981 (4,692; 2,718)
Total costs 42,947 (47,610; 13,317) 118,784 (133,554; 31,252) 42,947 (47,610; 13,317) 47,852 (53,978; 24,538) 111,951 (125,719; 30,623)
asp: asparaginase; E.coli-asp:  native E.coli asparaginase; PEG-asp:  PEGasparaginase; Erw-asp:  Erwinia asparaginase; na: not applicable.
by a switch to Erwinia asparaginase is the most expensive
alternative with overall costs of $ 103,474 (scenario 2).
We have shown that the distribution of the calculated
and simulated costs was mainly accounted for by asparagi-
nase use (47%) and that these asparaginase costs were
mainly determined by allergy percentages necessitating a
switch to Erwinia asparaginase. So, reducing the number of
allergies by using PEGasparaginase would also reduce costs.
Furthermore, PEGasparaginase is administered less fre-
quently than native E. coli asparaginase or Erwinia asparagi-
nase and is less immunogenic.19,20 Scenarios 1 and 3 were
less expensive than scenario 2; scenario 1 with
PEGasparaginase as first-line treatment is the most patient-
friendly option. For these reasons, PEGasparaginase is being
used as the first-line drug in induction and intensification in
the new DCOG ALL-11 protocol (opened in April 2012).
Two earlier studies investigated the costs of
PEGasparaginase. Both found that treatment costs with
PEGasparaginase were similar or slightly less than those
with native E. coli asparaginase.11,12 This is in line with our
observations. However these studies did not study costs
related to asparaginase allergy and in these studies asparag-
inase was given less intensively. Litsenburg et al. also stud-
ied costs in the ALL-10,13 but they calculated costs for the
total period of treatment and did not study the exact role of
asparaginase-related costs.
The costs in the different scenarios were based on actual
resource utilization in childhood ALL patients. We also
accounted for the costs of discarding unused asparaginase
vials by calculating the costs per used vial. Despite of the
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haematologica | 2013; 98(5) 757
Figure 3. One-way sensitivity analy-
ses of three asparaginase treat-
ment scenarios. Each bar indicates
treatment costs per patient when
the allergy probability or the costs
were varied from the lowest to the
highest value. The vertical line indi-
cates the base case value. (A)
Treatment costs with
PEGasparaginase (scenario 1). The
first bar represents the allergy
probability ranging from 25% to
100%. In the second and third bars
the costs were varied in non-aller-
gic (minus 25% to 25%) and aller-
gic patients (minus 25% to 200%),
respectively. (B) Treatment costs
with native E. coli asparaginase
(scenario 2). The first bar repre-
sents the allergy probability rang-
ing from 14% to 100%. In the sec-
ond and third bars the costs were
varied in non-allergic (minus 25%
until 25%) and allergic patients
(minus 25% until 200%), respec-
tively: 200% indicates the new
price of Erwinia asparaginase
(price level as of March 14, 2011).
(C) Treatment costs with native E.
coli asparaginase (scenario 3). The
first bar represents the allergy
probability ranging from 14% to
100%. The second bar shows the
allergy probability ranging from
40% to 100%. In the third bar the
costs were varied in non-allergic
patients (minus 25% to 25%). The
fourth bar represents the costs in
patients allergic to native E.coli
asparaginase (minus 25% to 25%).
The last bar shows the costs of
patients allergic to native E.coli
asparaginase and subsequently to
PEGasparaginase (minus 25% to
200%).
A
B
C
Treatment costs (n=84) with PEGasparaginase (scenario 1) ($)
Costs total group
allergy probability for
PEGasparaginase
71,810 113,558
82,66460,954
64,172
59,642 133,554
107,63999,308
81,771
52,519 82,674
70,402
66,236
65,139
62,230 103,089
74,568
75,665
98,381
190,284
100,199
40,000 60,000 80,000 100,000 120,000 140,000
40,000 60,000 80,000 100,000 120,000 140,000 160,000 180,000 200,000
40,000 60,000 80,000 100,000 120,000 140,000
Costs subgroup no
allergy
Costs subgroup with allergy
Costs total group
allergy probability for
native E. coli asp
Costs subgroup no
allergy
Costs subgroup with allergy
Costs total group allergy probability
for native E. coli asparaginase
Costs total group allergy probability for
PERGasparaginase
Costs subgroup no allergy
Costs subgroup allergy of
native E.coli asparaginase
Costs subgroup allergy of native E.coli
asparaginase and PEGasparaginase
Treatment costs (n=84) with native E.coli asparaginase (scenario 2) ($)
Treatment costs (n=84) with native E.coli asparaginase (scenario 3) ($)
sensitivity analysis to account for different percentages of
asparaginase-related allergy, it is important to note that
these percentages depend on several factors such as dose
schedule and the type of asparaginase, earlier exposure to
asparaginase in induction and the route of asparaginase
administration (intravenous or intramuscular).21
PEGasparaginase has been shown to result in less antibody
formation than native E. coli asparaginase.22 The percentage
of patients switching to another asparaginase preparation
can also depend on silent inactivation of asparaginase.9
With monitoring of asparaginase activity levels, more cases
of inactivation will be detected, necessitating a switch in
asparaginase preparations more often. 
This study had some limitations. First, we had to simu-
late part of the treatment in order to calculate costs. To
achieve reliable simulations for treatment with native E. coli
asparaginase, simulations were based on the allergy rates in
the ALL-9 HR and ALL-10 MR protocols. Furthermore,
some satellite hospitals were not visited to collect data,
which were retrieved from academic hospital files. A mean
cost based on data collected from satellite hospitals was
imputed for the missing data. We did not evaluate silent
inactivation of asparaginase; this is now being done in a
prospective setting. The generalizability of this study might
be limited, because there is tremendous heterogeneity
across the world in dose, frequency and type of asparagi-
nase used in the treatment of childhood ALL. Nowadays,
the new childhood ALL treatment protocols also include
PEGasparaginase, for instance in Germany23 and the United
Kingdom,24 while native E. coli asparaginase and Erwinia
W.H. Tong et al.
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Figure 4. Two-way sensitivity analyses of
three asparaginase treatment scenarios.
Each graph indicates the comparison
between two hypothetical scenarios 2
and 3 with scenario 1 as baseline. For
each allergy probability the values are
varied, represented as the vertical line or
the horizontal line. The intercept between
these lines indicates the base case value.
In all graphs, the horizontal axis is the
same. The light color area indicates for
which allergy probability combinations
the treatment costs with scenario 1 are
the lowest. The dark color area indicates
for which allergy probability combina-
tions the treatment costs with scenario 2
in (A) or scenario 3 in (B) and (C) are the
lowest. The line between the light and
dark colored area represents equal costs
in each comparison. (A) For the vertical
axis the probability of native E.coli
asparaginase allergy (scenario 2) is used.
(B) For the vertical axis the probability of
PEGasparaginase allergy (scenario 3) is
used. For the costs of scenario 3, the
probability of native E. coli asparaginase
is assumed to be 0.65. (C) For the verti-
cal axis the probability of native E. coli
asparaginase allergy (scenario 3) is used.
For the costs of scenario 3, the probabili-
ty of PEGasparaginase is assumed to be
0.4. Prob.: probability, E. coli-asp: native
E. coli asparaginase, PEG-asp:
PEGasparaginase.
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asparaginase are used in different countries. We studied the
costs of asparaginase preparations which were related to
different allergy probabilities. Additionally, the costs were
presented for 2 weeks of exposure to asparaginase. Taken
together, our results could be generalized for these countries
using different asparaginase preparations.
To conclude, we have shown that the costs of
PEGasparaginase and native E.coli asparaginase in intensi-
fication therapy are comparable. However,
PEGasparaginase is preferred, because it is administered
less frequently, requiring fewer daycare visits and is,
therefore, more patient-friendly. PEGasparaginase is less
immunogenic than native E. coli asparaginase and is not
more expensive. Since the price of Erwinia asparaginase
has been doubled, the saving of costs will be clearly in
favor of PEGasparaginase. Finally, asparaginase costs are
mainly determined by allergy rates, necessitating a switch
to Erwinia asparaginase.
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